Loading organizations...
Key people at re.Mind Capital.
re.Mind Capital is an early-stage venture capital firm that invests in companies focused on mental and neurological health. The firm targets advancements in new pharmaceutical approaches, innovative treatment modalities, brain-computer interfaces, and digital health solutions. It aims to back foundational technologies and therapies that address the complex challenges within the human mind.
Founded in 2020, re.Mind Capital emerged as the mental health-focused venture arm of serial entrepreneur and investor Christian Angermayer’s family office, Apeiron Investment Group. The firm was established with the insight that significant, specialized investment was needed to address pervasive global challenges in mental and neurological health, leveraging Angermayer’s extensive experience in entrepreneurship.
re.Mind Capital partners with founders developing breakthrough solutions in the mental and neurological health sectors. Its long-term vision is to significantly impact human well-being by backing companies that tackle some of humanity's most pressing health issues, fostering innovation that improves brain health and overall human flourishing for future generations.
re.Mind Capital is a venture capital fund specializing in early-stage investments focused on mental health, brain health, and neurological innovation. It supports visionary founders developing radical new solutions across sectors such as biotech, neuroscience, digital health, brain-computer interfaces, and new pharmaceutical modalities. The fund targets companies with scalable business models that address pressing mental and neurological health challenges, investing primarily at seed and growth stages with investment sizes ranging from $1 million to $50 million. Geographically, it operates across the United States, Europe (including Germany, the UK, Malta, Luxembourg), and Abu Dhabi, aiming to foster transformative innovation in mental health care and related technologies[1][2][3][6].
Founded in 2020 as the mental health investment arm of Apeiron Investment Group, re.Mind Capital was established by Christian Angermayer, a serial entrepreneur and investor, alongside partners Jan Hardorp and Max de Vere. The fund emerged from a recognition of the urgent need for breakthrough solutions in mental and neurological health, leveraging deep domain expertise and a commitment to supporting pioneering founders. Since its inception, re.Mind Capital has evolved to become a leading early-stage investor in mental health and brain health technologies, with a portfolio that includes companies developing brain-computer interfaces and novel biotech therapies. Early traction includes backing startups like Ksana Health, which focuses on objective mental health monitoring, and participation in significant biotech IPOs[1][2][3][5].
re.Mind Capital rides the growing global trend toward prioritizing mental health and neurological well-being, a sector gaining urgency due to rising awareness and demand for innovative care solutions. The timing aligns with advances in biotech, digital health, and brain-computer interface technologies, which are unlocking new treatment modalities and diagnostic tools. Market forces such as increasing mental health challenges worldwide, regulatory support for digital therapeutics, and technological breakthroughs create a fertile environment for re.Mind Capital’s investments. The fund influences the ecosystem by accelerating the commercialization of cutting-edge mental health innovations and fostering a network of startups that could redefine brain health care[1][2][3].
Looking ahead, re.Mind Capital is poised to deepen its leadership in mental and brain health investing, potentially expanding its portfolio in brain-computer interfaces and biotech innovations. Trends such as personalized mental health care, AI-driven diagnostics, and neurotechnology advancements will likely shape its investment focus. As mental health continues to gain prominence globally, re.Mind Capital’s influence may grow, driving new standards in how mental and neurological conditions are treated and managed. Its ongoing support for early-stage ventures positions it to capitalize on emerging opportunities and contribute meaningfully to human flourishing[2][3][6].
Key people at re.Mind Capital.
re.Mind Capital has 10 tracked investments across 10 companies. The latest tracked deal is $19.0M Series A in Motif Neurotech in January 2024.
